Barriers and Facilitators to Implementation of Intravenous Cardiovascular Treatments in Ambulatory Settings
Authors' conclusion
As novel IV treatments emerge, addressing barriers and leveraging facilitators preemptively can enhance the successful implementation of IV therapies and improve clinical outcomes in ambulatory settings.
Study context
- Population
- Ambulatory patients receiving intravenous (IV) cardiovascular therapies15 studies
- Outcome
- Barriers and facilitators to implementation of IV therapies in ambulatory settings
Methodological detailsthematic analysis, Studies primarily from North America and Europe, MEDLINE, Embase and CINAHL searched from inception to September 2023
- Thematic analysis
- Studies primarily from North America and Europe
- MEDLINE, Embase and CINAHL searched from inception to September 2023
Main finding
As reported in the abstract
- Medication-level barriers: need for multiple vials and lengthy preparation
- Patient-level barriers: adverse effects, infections, painful venous access and non-adherence
- Clinician-level barriers: understaffing, time constraints and safety concerns
- Institutional barriers: staff or equipment shortages, liability concerns and complex logistics
- Healthcare system barriers: financial constraints and limited care delivery services
- Facilitators: evidence-based indications, patient education and comfort, staff experience, guidance documents, safe settings, favourable insurance policies and supportive guidelines
- Methodologies varied, precluding quantitative synthesis
Original publication
Barriers and Facilitators to Implementation of Intravenous Cardiovascular Treatments in Ambulatory Settings. ESC Heart Fail. Published 25 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →